Classification of luminal subtypes as ER-positive and that of HER2+ and basal-like as ER-negative is endorsed by recent transcriptomic profiling of 35 276 cells from 32 breast cancer cell lines capturing the percentage of cells positive for expression of ESR1 and various EMT players in cell lines representing different breast cancer subtypes. This evidence concerns the gene ESR1 and breast cancer.